Isomorphic Labs reportedly seeks funding at a valuation of at least $40 billion

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, is reportedly in early talks to raise money at a valuation of at least $40 billion. Bloomberg reported the discussions on October 8, 2026, citing sources. The number could climb higher, potentially reaching as much as $50 billion. The talks are preliminary, and no deal has been finalized. From $17.5 billion to $40 billion and beyond Before these negotiations began, Isomorphic was valued at approximately $17.5 billion. The timing stands out too. Isomorphic closed a $2.1 billion Series B round only five months earlier, in May 2026. That round drew Thrive Capital, Alphabet, and the UK Sovereign AI Fund. The Series B followed a $600 million Series A in March 2025, which Thrive also led. In total, Isomorphic has raised approximately $2.7 billion in disclosed external funding since its founding. Alphabet remains the majority owner. What investors are actually buying Isomorphic was founded in 2021 as a spin-off of DeepMind and is led by CEO Demis Hassabis. Its core product is IsoDDE, short for the Isomorphic Drug Design Engine. The platform builds on AlphaFold, DeepMind’s technology for predicting protein structur...